Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02255175 · ClinicalTrials.gov registry record · Phase 4

Perimenopausal Effects of Estradiol on Reward Responsiveness

A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 4
Development phase
64
Enrollment target

NCT02255175 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 64 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02255175, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 4
Development phase
64 participants
Enrollment target

Study Summary

Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women either with or without depression.

Interventions

  • DRUG Progesterone
  • DRUG Estradiol

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2015-10-01
Est. Completion 2018-10-17
Phase Phase 4

What the Registry Record Tells You About NCT02255175

The ClinicalTrials.gov registry entry for NCT02255175 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Progesterone is the first listed.

NCT02255175 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02255175 about?

NCT02255175 is a clinical study titled "Perimenopausal Effects of Estradiol on Reward Responsiveness". Using neuroimaging, the investigator will study the effects of estrogen on mood and brain function in perimenopausal women either with or without depression.

What is the current status of trial NCT02255175?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2015-10-01. Estimated completion is 2018-10-17.

What interventions are being tested in trial NCT02255175?

The interventions under investigation include: Progesterone (DRUG), Estradiol (DRUG).

Who is sponsoring clinical trial NCT02255175?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.